ProACT Post-Approval Study
Uromedica · NCT03767595
Opens the official ClinicalTrials.gov record, with the study team’s contacts. Bored Studies doesn’t enroll anyone.
Key facts
- Compensation
- Not posted. Ask the study team before screening.
- Who can join
- Ages 50+ · Men only
- Healthy volunteers
- Accepted
- Study type
- Interventional · Not applicable
- Target enrollment
- 145
- US sites recruiting
- 14
- Study start
- February 19, 2019
- Record last updated
- October 6, 2026
Status re-checked against ClinicalTrials.gov within the last 12 hours.
What the study is about
The ProACT Post Approval Study is a 5-year prospective, open-label, multi-center study designed to evaluate the long-term incidence of urethral stricture and device erosion after ProACT implantation. In addition, the study will evaluate whether treatment with ProACT affects clinical outcomes after subsequent SUI therapies.
Being studied: ProACT Adjustable Continence Therapy for Men
Conditions: Stress Urinary Incontinence
Eligibility criteria
Copied from the official record. The study team makes the final decision at screening.
Show full criteria
Inclusion Criteria
- Subject is a male of at least 50 years of age.
- Subject demonstrates stress urinary incontinence.
- Subject has undergone a radical prostatectomy, transurethral resection of the prostate, or other prostate surgery.
- Subject is willing and able to undergo surgical implantation of ProACT devices.
- Subject is willing and able to comply with study-required
follow-up activities, including annual telephonic follow -up interviews, for a period of 5 years from their date of initial implantation. This includes compliance even after possible explant of ProACT devices and/or possible implantation of subsequent therapies.
- Subject is willing and able to sign the approved informed consent.
- Subject has two positive 24-hour pad weight tests (greater than or equal to 8 gram pad weight increase demonstrated in two 24-hour pad weight tests).
- Subject has a negative urine culture.
- Subject has no known urogenital malignancy, other than previously treated prostate cancer.
- Subject meets ONE of the following criteria:
- Baseline Prostate-Specific Antigen (PSA) of less than or equal to 2.5ng/mL;
- Baseline PSA > 2.5ng/mL and less than or equal to 10 ng/mL AND free PSA greater than or equal to 25% of total PSA;
- Physician determines subject to be a suitable surgical candidate.
Exclusion Criteria
- Subject has an existing urethral stricture, a history of any urethral strictures, or has ever had a urethrotomy.
- Subject has undergone prostate surgery or any anti-incontinence surgery within the last 12 months.
- Subject has an artificial urinary sphincter or any components of a previously implanted artificial urinary sphincter in vivo.
- Subject has undergone radiation therapy in the prostatic area within the last 12 months.
- Subject has untreated or unsuccessfully treated detrusor instability or over-activity.
- Subject has an atonic bladder.
- Subject had, presently has, or is suspected of having bladder cancer.
- Subject has untreated or unsuccessfully treated bladder stones.
- Subject has detrusor sphincter dyssynergia.
- Subject has known hemophilia or a bleeding disorder.
- Subject has a known severe contrast solution allergy (e.g., anaphylaxis, cardiac, or respiratory arrest).
- Subject has insulin-dependent diabetes that is uncontrolled or not controllable, as indicated by an A1c test result of = 6.5%.
Recruiting US locations
University of Southern California
Los Angeles, CA 90033
Site contact: Julissa Morales · julissa.morales@med.usc.edu
Sutter Health
Santa Barbara, CA 93110
Site contact: Morgan Caldwell-Holden · morgan.caldwell-holden@sutterhealth.org
University of Colorado
Denver, CO 80045
Site contact: Andrea Pina · andrea.pinalimones@cuanschutz.edu
University of Florida
Gainesville, FL 32610
Site contact: John Marks, DHSc, CCRP · 352-273-5618 · John.Marks@urology.ufl.edu
Urological Research Network Corp
Hialeah, FL 33016
Site contact: Isabel Lopez · isabel@besturology.net
Emory University
Atlanta, GA 30322
Site contact: Nahir Imtiaz · sbimtia@emory.edu
University of Kansas Medical Center
Kansas City, KS 66103
Site contact: Kirk Redger, MD · 913-588-1227 · kredger@kumc.edu
University of Michigan
Ann Arbor, MI 48109
Site contact: Nailah Henry · hnailah@med.umich.edu
CentraCare- St. Cloud
Saint Cloud, MN 56303
Site contact: Andrew Windsperger, MD · 320-229-4547 · andrew.windsperger@centracare.com
CHI Health Research
Omaha, NE 68124
Site contact: Jan Mitchell · jan.mitchell@commonspirit.org
Lehigh Valley Health Network
Allentown, PA 18103
Site contact: Megan McGonagle, MSN, RN, PCCN · Megan.mcgonagle@jefferson.edu
Allegheny Health Network
Pittsburgh, PA 15212
Site contact: Rachel Reading · rachel.reading@ahn.org
Urology Partners of North Texas Research Institute
Arlington, TX 76017
Site contact: Grace Yoon · gyoon@folioclinicalresearch.com
DHR Health Institute for Research and Development
McAllen, TX 78504
Site contact: Clarisa Medina · c.medina@dhrhealth.com
Study contacts (from the official record)
- Matt Kelly, PhD · 6124698882 · usmtk@coloplast.com
- Lisa DRAPER · usldr@coloplast.com
Similar studies in California
All healthy volunteers studies in California →- RecruitingHealthy volunteersPhase 1Overnight stay mentioned
A Study to Investigate the Relative Bioavailability and Safety of Different Oral Formulations of Elecoglipron in Healthy Participants
AstraZeneca
- Location
- Glendale, CA + 1 other US site
- Eligibility basics
- Ages 18–55
- RecruitingHealthy volunteersPhase 1Overnight stay mentioned
A Phase I Study to Investigate the Pharmacokinetics and Safety of Capivasertib in Participants With Moderate Hepatic Impairment
AstraZeneca
- Location
- Rialto, CA + 1 other US site
- Eligibility basics
- Ages 18–80
- RecruitingHealthy volunteersPhase 1Overnight stay mentioned
A Study to Learn How the Body Processes the Study Medicine PF-07328948 in People With Reduced Kidney Function
Pfizer
- Location
- Lake Forest, CA + 3 other US sites
- Eligibility basics
- Ages 18–80
- RecruitingHealthy volunteersPhase 1Overnight stay mentioned
Phase 1 Study of SBS-147 in Healthy Adults
Sparian Biosciences, Inc
- Location
- Cypress, CA
- Eligibility basics
- Ages 18–55